Letermovir is a human cytomegalovirus terminase inhibitor for cytomegalovirus infection prophylaxis in hematopoietic stem cell transplant recipients. Posaconazole (POS), a substrate of glucuronosyltransferase and P-glycoprotein, and voriconazole (VRC), a substrate of CYP2C9/19, are commonly administered to transplant recipients. Because coadministration of these azoles with letermovir is expected, the effect of letermovir on exposure to these antifungals was investigated. Two trials were conducted in healthy female subjects 18 to 55 years of age. In trial 1, single-dose POS 300 mg was administered alone, followed by a 7-day washout; then letermovir 480 mg once daily was given for 14 days with POS 300 mg coadministered on day 14. In trial 2, on day 1 VRC 400 mg was given every 12 hours; on days 2 and 3, VRC 200 mg was given every 12 hours, and on day 4 VRC 200 mg. On days 5 to 8, letermovir 480 mg was given once daily. Days 9 to 12 repeated days 1 to 4 coadministered with letermovir 480 mg once daily. In both trials, blood samples were collected for the assessment of the pharmacokinetic profiles of the antifungals, and safety was assessed. The geometric mean ratios (90%CIs) for POS+letermovir/POS area under the curve and peak concentration were 0.98 (0.83, 1.17) and 1.11 (0.95, 1.29), respectively. Voriconazole+letermovir/VRC area under the curve and peak concentration geometric mean ratios were 0.56 (0.51, 0.62) and 0.61 (0.53, 0.71), respectively. All treatments were generally well tolerated. Letermovir did not affect POS pharmacokinetics to a clinically meaningful extent but decreased VRC exposure. These results suggest that letermovir may be a perpetrator of CYP2C9/19-mediated drug-drug interactions.
Human cytomegalovirus (human herpesvirus 5; CMV) is a highly prevalent pathogen with seroprevalence rates varying across populations, ranging between 40% and 100% of the adult population.
1,2 After initial infection, CMV establishes a latent infection and typically remains clinically asymptomatic. However, following solid organ or hematopoietic stem cell transplantation (HSCT), CMV present in either the recipient or in donated tissue can become reactivated and cause disease in the immunocompromised host, potentially leading to life-threatening CMV-related manifestations. [3] [4] [5] Without antiviral prophylaxis, ß80% of seropositive HSCT recipients demonstrate symptoms of CMV infection. 5, 6 The most serious manifestation of CMV disease is CMV pneumonia, which is associated with a mortality rate of >50% when contracted by HSCT recipients. [5] [6] [7] Prophylactic and preemptive treatments are typically administered to prevent CMV disease in transplant recipients. However, current standard-of-care treatments-such as valganciclovir, foscarnet, and cidofovir-are associated with viral resistance and dose-limiting side effects, including bone marrow suppression and nephrotoxicity. [8] [9] [10] [11] Letermovir (also known as MK-8228 and AIC246) is a once-daily CMV terminase complex inhibitor recently approved for marketing in the United States, Canada and the European Union. 12, 13 Due to its mechanism of action, letermovir retains activity against viruses resistant to existing anti-CMV treatments. 14 Letermovir has demonstrated significant anti-CMV activity in preclinical studies 12, 14 and was studied as preemptive therapy in kidney transplant recipients and as prophylactic therapy in HSCT recipients, showing efficacy as well as an acceptable safety profile. 15, 16 In addition to antiviral therapies, antifungal prophylaxis may be considered for HSCT recipients to reduce the risk of opportunistic fungal infections, which contribute substantially to morbidity and infectionrelated mortality. 17 Posaconazole (POS) is currently recommended for the prophylaxis of fungal infections in high-risk patients with leukemia or HSCT patients. 18 Although not approved for prophylaxis of fungal infections, voriconazole (VRC) is often used as an alternative to POS 18 and has demonstrated similar antifungal prophylactic efficacy to fluconazole after 180 days in myeloablative HSCT recipients. 19 Following oral administration to healthy subjects, letermovir is rapidly absorbed with a median time to maximum plasma concentration of 0.75 to 2.25 hours, with a half-life of ß12 hours. 13 Steady state is achieved in 9 to 10 days. 13 Letermovir is primarily eliminated in the feces as parent compound via hepatic uptake by the organic anion-transporting polypeptide 1B1; no major metabolites are detected in plasma, and the most prominent metabolite is a glucuronide conjugate (6% of the dose) observed in feces. 13 The recommended therapeutic dose is 480 mg once daily. 13 Overall, letermovir has been generally well tolerated, and in a phase 3 trial 20 it has shown a similar safety profile to that of placebo in allogenic HSCT recipients. The most commonly reported adverse events (AEs) in this trial were nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain. 20 In vivo letermovir is a net inhibitor of cytochrome P450 (CYP)3A, demonstrating a weak to moderate inhibitory effect on CYP3A activity, indicated by an increase in exposure of midazolam, tacrolimus, and cyclosporine when administered in the presence vs absence of letermovir. 13 Additionally, concomitant administration of letermovir with digoxin, a known Pglycoprotein (P-gp) substrate, does not cause clinically meaningful drug-drug interactions (DDIs), suggesting that letermovir is not a P-gp inhibitor in vivo. 13 Based on the properties above, it is possible that letermovir interacts with the pregnane X receptor (PXR) or the constitutive androstane receptor, both of which influence the expression of genes involved in drug metabolism and distribution. Specifically, PXR is a transcriptional regulator of CYP3A4, CYP2B, and CYP2C families and other drug disposition enzymes, such as glutathione S-transferase, P-gp, multidrug resistance-associated proteins, and organic anion-transporting polypeptide. 21, 22 The constitutive androstane receptor is a regulator of genes controlling CYP2B, CYP2C, and CYP3A subfamilies, sulfotransferases, and glutathione-S-transferases. [23] [24] [25] [26] POS is excreted primarily as unchanged parent via the fecal/biliary route and is not metabolized to a significant extent. Approximately 66% of the unchanged parent drug is recovered in feces, 27 while the remaining POS components are recovered in the form of metabolites produced primarily via uridine diphosphate glucuronosyltransferase (UGT) 1A4. 28 Concomitant administration of rifampin reduces POS exposure by ß50%, most likely due to the induction of glucuronosyltransferases. 29 Posaconazole is both a substrate and inhibitor of P-gp. 30 In contrast, VRC is eliminated largely via hepatic metabolism by CYP2C19 and CYP2C9, with a minor contribution from CYP3A4. 31 Letermovir has the potential to affect the drugmetabolizing and clearance pathways of POS and VRC. As these antifungals are likely to be coadministered with letermovir in transplant recipients, 2 phase 1 drug interaction clinical trials were conducted in healthy subjects to investigate this possibility. Trial 1 (POS) evaluated whether letermovir influenced the elimination pathway of POS, and trial 2 (VRC) tested the potential for letermovir to alter CYP-mediated metabolism. Healthy women aged 18 to 55 years with a body mass index ࣙ18.5 to ࣘ32.0 kg/m 2 were eligible for inclusion. All subjects with childbearing potential were required to use an acceptable method of contraception. Only women were included in these trials, due to testicular toxicity observed in the rat male species (at ࣙ3-fold the recommended dosage) during preclinical toxicology studies; the relevance of this observation in humans was unknown at the time these trials were conducted. Subjects were confined on drug administration days to assure compliance with study drug administration.
Methods
Trial 1 (POS) was an open-label, 2-period, fixedsequence study design. In period 1, subjects received a single dose of POS 300 mg orally (3 100-mg delayedrelease tablets) following an overnight fast. Period 2 initiated following a washout interval of at least 7 days. Subjects received letermovir 480 mg once daily orally for 14 days. On day 14, following an overnight fast, a single dose of POS 300 mg was coadministered with letermovir. Blood samples for POS were collected at pre-POS dose and 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, and 168 hours postdose in period 1 and period 2. Safety was monitored throughout the study.
Trial 2 (VRC) was an open-label, fixed-sequence study design. Subjects received 2 doses of VRC 400 mg orally separated by 12 hours on day 1. On days 2 and 3, VRC 200 mg was administered every 12 hours. On day 4, a single dose of VRC 200 mg was administered. Letermovir 480 mg was administered orally once daily on days 5 to 8. VRC and letermovir were coadministered on days 9 to 12: letermovir 480 mg once daily and 2 doses of VRC 400 mg separated by 12 hours on day 9, then 200 mg every 12 hours on days 10 and 11, with a single 200-mg dose administered on day 12. Subjects were administered study drugs following an overnight fast on days 4 and 12. Voriconazole was dosed at least 1 hour before or after meals on other days. Blood samples for VRC were collected predose day 1 and predose and 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours postdose on days 4 and 12. Safety was monitored throughout the study.
Pharmacokinetic Evaluations
Posaconazole plasma concentrations were assessed using ultra performance liquid chromatography with tandem mass spectroscopy by PPD (Middleton, Wisconsin). The POS lower limit of quantification was 5 ng/mL. Daily standard curves indicated that POS measurement precision (standard deviation [SD]/mean calculated concentration) ranged from 1.82% to 11.0%, and measurement accuracy ([mean calculated concentration/nominal concentration] x100) ranged from 97.1% to 101.8%.
Voriconazole plasma concentrations were determined by InVentiv Health Clinique, Quebec, Canada, using liquid chromatography with tandem mass spectroscopy. The lower limit of quantification for VRC was 5 ng/mL. From analysis of daily standard curves, measurement precision ranged from 1.87% to 4.03%, and measurement accuracy ranged from 97.79% to 100.96%.
Pharmacokinetic (PK) parameter values for POS and VRC were determined using WinNonlin version 6.3 (Certara, LP, St. Louis, Missouri). Values of the following parameters were calculated: area under the plasma concentration-time curve from time 0 to infinity (AUC 0-Ý ), AUC from time 0 to the last measurement (AUC 0-last ), maximum plasma concentration (C max ), plasma concentration at 24 hours post-dose (C 24 ), time to maximum plasma concentration, and terminal halflife for POS; AUC from time 0 to 12 hours (AUC 0-12 ), C max , plasma concentration at 12 hours post-dose (C 12 ), and time to maximum plasma concentration for VRC.
Safety Assessments
The safety of the treatments was assessed throughout both studies by monitoring AEs, vital signs, 12-lead electrocardiograms, and clinical laboratory tests.
Data Analysis
Statistical analyses were performed using Statistical Analysis Software Version 9.2 or higher (SAS Institute, Cary, North Carolina). Linear mixed-effects model including a fixed-effect term for treatment was applied. An unstructured covariance matrix was used to allow for unequal treatment variances and to model correlation between the 2 treatment measurements within each subject via the REPEATED statement in SAS PROC MIXED. Kenward and Roger's method was used to calculate denominator degrees of freedom for fixed effects (DDFM = KR). 32 Further, the geometric mean ratios (GMRs, antifungal + letermovir/antifungal alone) with 90%CIs were calculated for AUC 0−Ý , C max , AUC 0−last , and C 24 for POS, and for AUC 0−12 and C max for VRC.
The as-treated population comprised all subjects who received at least 1 dose of study drug and was used for assessments of safety and tolerability. The per-protocol population included all subjects who had complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of treatment; all compliant subjects with available data from at least 1 treatment were included in this population, which was used for the PK analysis.
Determination of Sample Size
The intersubject SD of POS ln-AUC 0−Ý was estimated to be 0.271 based on previous study data. If the true GMR of POS AUC 0−Ý (POS + letermovir /POS alone) was 1.00, then 14 subjects would provide the study with >99% probability of observing the 90%CI for AUC 0−Ý was >0.50. If the true AUC 0−Ý GMR was ࣙ0.65, then 14 subjects would provide the study with ࣙ80% probability that the 90%CI was >0.50. In addition, 2 extra subjects were included into the study to account for potential discontinuations. Therefore, 16 subjects were enrolled into this study.
Using pooled estimates from published studies, we estimated the within-subject SD of VRC log AUC 0-12 and log C max to be 0.2886 and 0.2554, respectively. With 14 subjects receiving VRC alone or coadministered with letermovir, the lower and upper 90%CI for the true GMR of AUC 0-12 (VRC + letermovir/VRC alone) would be given by observed GMR/1.1464 and observed GMR x 1.1464. Thus, if the observed AUC 0-12 GMR was 1, the 90%CI would be 0.87 to 1.15. With 14 subjects receiving VRC alone or coadministered with letermovir, the lower and upper 90%CI for the true GMR of C max (VRC + letermovir/VRC alone) will be given by observed GMR/1.1285 and observed GMR x 1.1285. Therefore, if the observed C max GMR was 1, the 90%CI would be 0.89 to 1.13.
Results

Study Population
In trial 1 (POS), a total of 16 subjects enrolled, and 13 subjects completed per protocol. A single subject was discontinued due to a protocol violation before period 2; additionally, 2 subjects were discontinued before period 2 at the investigator's discretion. In trial 2 (VRC), a total of 14 subjects enrolled, and 12 subjects completed per protocol. One subject was discontinued on day 5 at the investigator's discretion, and 1 subject withdrew consent on day 10. No subjects were discontinued due to AEs in either study. Subject demographics for both trials are shown in Table 1 . BMI, body mass index; max, maximum; min, minimum; N, number of subjects exposed; n, number in subgroup. 
Plasma Pharmacokinetics
The mean plasma concentration-time curves for POS and VRC in the presence or absence of concomitantly dosed letermovir are shown in Figure 1 . The corresponding PK parameter values are shown in Table 2 , and GMRs for AUC and C max in Figure 2 . The plasma concentrations of POS were minimally affected with letermovir coadministration, with the GMRs (POS + letermovir/POS) for AUC 0-Ý , AUC 0-last , C max , and C 24 all within 0.98 to 1.11. In contrast, VRC steady-state plasma AUC 0-12 and C max were decreased by approximately 44% (GMR 0.56; 90%CI 0.51, 0.62) and 39% (GMR 0.61; 90%CI 0.53, 0.71), respectively, when coadministered with letermovir vs administered alone.
Safety
In trial 1 (POS), a total of 26 AEs were reported by 10 subjects. All AEs were of mild intensity and resolved by study completion. Three vessel puncture site reactions were reported in period 1, all of which were related to blood vessel puncture before administration of POS. A total of 23 AEs were reported in period 2; of these, 20 were considered to be possibly or probably related to letermovir. The most common AEs (incidence of ࣙ2 subjects) were nausea, headache, abdominal discomfort, upper abdominal pain, back pain, dizziness, and hot flush. One subject in trial 1 received a single oral dose of 650 mg acetaminophen for back pain relief; this drug did not interfere with PK measurements of POS. All other AEs resolved without use of concomitant medication. Three AEs (upper abdominal pain, diarrhea, and dizziness) were considered to be possibly or probably related to POS.
In trial 2 (VRC), a total of 6 AEs were reported by 4 subjects. All AEs were mild to moderate in intensity and resolved by study completion. Five AEs were considered to be treatment-related. Nausea was the most commonly reported AE (incidence of ࣙ2 subjects).
No serious AEs or AEs that led to discontinuation occurred in either the VRC or the POS studies. In addition, no changes were seen in electrocardiograms, nor were there hematologic, urinary, or hepatic laboratory tests that suggested a relationship to letermovir in either study.
Discussion
Letermovir is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of CMV infection and disease. Because letermovir may be coadministered with the azole antifungals POS and VRC in transplant recipients, a DDI investigation was conducted, as letermovir has the potential to affect drug-metabolizing enzymes and transport proteins, including those important in the disposition of commonly used antifungals. The clinical dose of letermovir 480 mg was evaluated as a potential perpetrator of DDIs with POS (metabolized by UGT1A4 and substrate of P-gp) and VRC (metabolized by CYP2C9 and CYP2C19, and to a minor extent by CYP3A).
In trial 1 (POS), letermovir did not affect the PK of POS to a clinically meaningful extent. POS is predominantly eliminated in the feces as the parent drug; however, it is also metabolized by UGTs, and strong inducers of UGTs decrease POS plasma concentrations by ß50%. 33 The lack of an observed effect of letermovir on POS PK could be explained by UGT1A4 being unaffected by letermovir in vivo. In addition, lack of effect further supports that letermovir is not a Pgp inhibitor. A potential limitation of trial 1 is the cessation of dosing at day 14, whereas PK sampling continued to 168 hours. For full drug interaction effects, ideally, continued dosing of letermovir through the PK sampling interval is preferred. Dosing run in through 14 days should have provided steady-state effects to reasonably assess drug interaction effects. C max , time to C max , and C 24 (parameters assessed within the oncedaily dosing interval of POS) were not impacted to a clinically meaningful extent (mean maximum increase of 11%), and continued letermovir dosing, which would potentially impact AUC 0-Ý and AUC 0-last , would likely not have demonstrated an effect larger than that seen with the above parameters.
In contrast, VRC exposure (trial 2) was decreased in the presence vs absence of letermovir by ß44% and ß39% for AUC 0-12 and C max , respectively. The decrease in exposure is likely due to the induction of CYP2C9 and CYP2C19, which could be secondary to letermovir-mediated activation of PXR. 24, 25 Mean decreases of ß82% and ß67% in VRC AUC 0-12 and C max , respectively, were observed in interaction studies with VRC and the known CYP2C19/CYP2C9 inducers ritonavir and efavirenz. 34, 35 All of the treatment combinations were generally well tolerated. The plasma concentration of POS was largely unaffected by coadministration with the intended clinical dose of letermovir 480 mg daily vs without. This result suggests that letermovir 480 mg may be administered with POS without requiring dose adjustment. In contrast, letermovir 480 mg moderately decreased exposure of VRC. Therefore, close monitoring for reduced effectiveness of VRC is recommended on coadministration with letermovir. The drug interaction studies were conducted in healthy women; however, the magnitude of these DDIs should be generally equivalent in the target patient population, as there are no data to suggest that the clearance pathways should be affected by disease state or sex. 13 The impact of POS and VRC on letermovir PK was not assessed in these studies, as the profiles of POS and VRC do not indicate that these compounds would impact the PK of letermovir. POS is a strong inhibitor of CYP3A, 33 and VRC inhibits the activity of CYP2C19, CYP2C9, and CYP3A4 in vitro, 36 none of which is a major elimination pathway of letermovir.
Conclusions
The PK of POS is not affected by coadministration with letermovir to a clinically meaningful extent. In contrast, VRC exposure is decreased when it is coadministered with letermovir compared to without, likely secondary to CYP2C9/19 induction. Close monitoring of reduced effectiveness of VRC is recommended with coadministration of letermovir.
